Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection
about
Adaptive immunity to fungiCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.Identification and cloning of a cryptococcal deacetylase that produces protective immune responsesInsights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosisEffects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsuleBivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyces dermatitidisAntibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cellsPhase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune miceBoth Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.Characterization of two novel cryptococcal mannoproteins recognized by immune sera.Immunoregulation by capsular components of Cryptococcus neoformans.Antifungal agents: chemotherapeutic targets and immunologic strategies.Epidemiology of cryptococcal meningitis in the US: 1997-2009.Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodiesCryptococcal infection and Th1-Th2 cytokine balance.Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophagesAnalysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.Antibody immunity and invasive fungal infectionsOpsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodiesPeptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.Acute lethal toxicity following passive immunization for treatment of murine cryptococcosisExtracellular proteins of Cryptococcus neoformans and host antibody responseReactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.Methylation of glycosylated sphingolipid modulates membrane lipid topography and pathogenicity of Cryptococcus neoformans.The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding.Antifungal immunotherapy and immunomodulation: a double-hitter approach to deal with invasive fungal infections.Toward identification of the genetic risk profile for cryptococcal disease in HIV-infected patientsThe capsule of the fungal pathogen Cryptococcus neoformans.Pharmacotherapy of cryptococcosis.Potential of anti-Candida antibodies in immunoprophylaxis.
P2860
Q27025806-BC09C2FA-E986-42A1-B0E4-9343F9BD0797Q30424017-66A8E8BC-86CE-4B39-9FCD-2D9E612DCC06Q30729695-4EED3925-DCCC-4715-AF7F-9495568FA61BQ33499671-57E06C12-0B62-4303-AE70-A74314CC9A14Q33556039-1482D944-8329-46F5-99A3-20B0EC9222BAQ33693515-284D4FC1-D28E-472E-B3E4-51F6EDD70B92Q33751411-3791323C-6131-455C-A7AF-6B3B99FE1A98Q33752366-40696703-F654-4859-BA7A-F2919FC000B1Q33752377-4F645017-7BCD-4CD4-9420-8C13FD35CA0AQ33754371-EB92C757-EBAC-4D6B-8FA3-518B231C0898Q33767890-2F2B1305-99F1-4DEE-AED1-BE7BA5CE0C85Q33793546-D1737B16-F694-4DB7-9406-A5D5845D8AB5Q33857658-DF02DAD3-002D-45AE-88F8-48B3228A3F41Q34001701-55A2CF6C-1989-454C-A174-6ED413394C28Q34009446-3AA1434A-A482-4E59-8234-EB73FCB4A1ADQ34111740-7EF3FB13-5143-4BC1-A3B3-6FE881C0CBDDQ34155052-80C7E370-BEB0-4231-95B6-97287E05905FQ34400044-A37FC0C0-2A22-428D-A98E-464E258690A5Q34606681-7793ACCA-9CE0-4A9A-A752-B5772FE69888Q34757345-8AA37A1D-57C8-4B97-B5B6-E5FE1B69EAE2Q35027538-A56D97E0-88FD-48EF-9435-D454F201CBACQ35115708-7CB83E37-A6E0-4DD4-901B-C4546B70C3ABQ35386000-6B59947E-68BA-43EE-BE83-FA2823AA34D0Q35428887-0F79E247-55F2-453B-8C58-01B004AAA43BQ35434901-045EBABD-E7F1-451C-8CFC-8CF07FB9F586Q35447692-A8A18054-E665-40D7-B119-141E17B000BAQ35514947-9D2B2A69-0829-447E-AB00-6E96E9A97D2FQ35544888-D864153E-BEDB-4BDE-9256-DC1F33FEBFD5Q35546751-214D4D29-F838-40CD-AF86-A0919677B415Q35550533-C412B18B-6A17-4047-93C5-8F37C748D78CQ35567548-4A0105F7-D32B-4322-AE4E-5159C1E9BA8EQ35775466-FC6E91A2-C511-4639-953F-8E8F782EAE0DQ35827998-CA86F799-D8EE-4E1F-889F-BFC22FE88F2BQ35913526-8A58DFD3-A994-4D4A-AFAA-398B12317FD9Q36350251-C0BFBDED-6058-4FA6-A14E-079DE526932BQ37132306-A1731AF3-E42D-4178-A8DD-EFBDFA73D383Q37267079-F031C937-456A-45DD-B11F-435B9DB155CEQ37337879-CB69ECAD-4CE5-4D31-A49E-798DB0B2BBA1Q37587230-353C3E09-D4D6-41EB-9972-9C99BE137F5FQ37773252-D472D737-4AF4-403B-A516-3980F2300A45
P2860
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Antibody-mediated protection i ...... ptococcus neoformans infection
@ast
Antibody-mediated protection i ...... ptococcus neoformans infection
@en
type
label
Antibody-mediated protection i ...... ptococcus neoformans infection
@ast
Antibody-mediated protection i ...... ptococcus neoformans infection
@en
prefLabel
Antibody-mediated protection i ...... ptococcus neoformans infection
@ast
Antibody-mediated protection i ...... ptococcus neoformans infection
@en
P2093
P2860
P356
P1476
Antibody-mediated protection i ...... ptococcus neoformans infection
@en
P2093
A Casadevall
J Mukherjee
L A Pirofski
M D Scharff
P2860
P304
P356
10.1073/PNAS.90.8.3636
P407
P577
1993-04-01T00:00:00Z